Generics the winners in Chinese regulatory overhaul?
This article was originally published in SRA
As debate continues over Chinese President Xi Jinping's true commitment to meaningful reforms, sweeping draft revisions to drug registration regulations laid out by the China Food and Drug Administration earlier this month1,2 show parts of the bureaucracy are already forging ahead.
You may also be interested in...
French giant makes its biggest single investment to date in Asia as it prepares to build up regional vaccine production capacity, in part to help prepare for future pandemics.
In this week's podcast version of Five Must-Know Things, hear about whether safety concerns may affect JAK inhibitors, Takeda’s strategic R&D plans, Cigna’s psoriasis insurance program, Phase III readouts to look for, and an overview of the global pharma R&D pipeline.
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio